We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 8.20% | 3.30 | 2.60 | 4.00 | 0.00 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 6.78 | 9M |
TIDMPRM
RNS Number : 7701D
Proteome Sciences PLC
28 April 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) -------------------------------------------------------------------------------------------- 1. Identity of the issuer or PROTEOME SCIENCES PLC the underlying issuer of existing shares to which voting rights are attached: (ii) ------------------------------------------------------------- ----------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): -------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights YES ---------------------------------------------------------------- -------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ---------------------------------------------------------------- -------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ---------------------------------------------------------------- -------------------------- An event changing the breakdown of voting rights ---------------------------------------------------------------- -------------------------- Other (please specify): ------------------------------------------------------- ------- -------------------------- 3. Full name of person(s) VULPES LIFE SCIENCES FUND subject to the VULPES TESTUDO FUND notification obligation: (iii) --------------------------------------------------------- --------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) --------------------------------------------------------- --------------------------------- 5. Date of the transaction 27 APRIL 2017 and date on which the threshold is crossed or reached: (v) --------------------------------------------------------- --------------------------------- 6. Date on which issuer 28 APRIL 2017 notified: --------------------------------------------------------- --------------------------------- 7. Threshold(s) that is/are >18% crossed or reached: (vi, vii) --------------------------------------------------------- --------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of voting % of voting of of of shares rights rights (x) Shares Voting Rights ------------- --------------- --------------- ------------- --------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- ------------- ------------- ------------ ------------ ----------- GB0003104196 53,943,715 53,943,715 54,043,715 54,043,715 18.34% --------------- --------------- ------------- ------------- ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------ ----------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights instrument (xvii) period refers to (xix, xx) (xviii) --------------- ------------- ------------- --------------- ----------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- --------------- ----------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 54,043,715 18.34% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) --------------------------------------------------------------------------------------------- Proxy Voting: --------------------------------------------------------------------------------------------- 10. Name of the proxy holder: -------------------------------------------------------------- ----------------------------- 11. Number of voting rights proxy holder will cease to hold: -------------------------------------------------------------- ----------------------------- 12. Date on which proxy holder will cease to hold voting rights: -------------------------------------------------------------- ----------------------------- executive.pa@proteomics.com 13. Additional information: ------------------------------------------------------------ ------------------------------- 14. Contact name: Victoria Birse ------------------------------------------------------------ ------------------------------- 15. Contact telephone number: ------------------------------------------------------------ ------------------------------- Note: Annex should only be submitted to the FCA not the issuer Annex: Notification of major interests in share A: Identity of the persons or legal entity subject to the notification obligation ----------------------------------------------------------------------- Full name VULPES LIFE SCIENCES FUND (including legal form of legal entities) ------------------------------------ --------------------------------- Contact address c/o Maples Corporate Services (registered office for legal Limited, PO entities) Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands ------------------------------------ --------------------------------- Phone number & email ------------------------------------ --------------------------------- Other useful information (at least legal representative for legal persons) ------------------------------------ --------------------------------- B: Identity of the notifier, if applicable ----------------------------------------------------------------------- Full name Stephen Diggle ------------------------------------ --------------------------------- Contact address One George Street #07-03 Singapore 049145 ------------------------------------ --------------------------------- Phone number & email Tel: (65) 6538 1998 (Main) Email: sdiggle@vulpesinvest.com ------------------------------------ ---------------------------------
Other useful information Director (e.g. functional relationship with the person or legal entity subject to the notification obligation) ------------------------------------ --------------------------------- C: Additional information ----------------------------------------------------------------------- Email address: Complete the required TR-1 form and email it to: Major shareholdings majorshareholdings@fca.gov.uk Fax number: You can print the TR-1 form, complete it and fax it to: 020 7066 0050 ----------------------------------------------------------------------- For notes on how to complete form TR-1 please see the FCA website.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUBCCUPMGAR
(END) Dow Jones Newswires
April 28, 2017 11:54 ET (15:54 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions